These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 20182024)

  • 1. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
    Prediger RD; Matheus FC; Schwarzbold ML; Lima MM; Vital MA
    Neuropharmacology; 2012 Jan; 62(1):115-24. PubMed ID: 21903105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
    Xu K; Bastia E; Schwarzschild M
    Pharmacol Ther; 2005 Mar; 105(3):267-310. PubMed ID: 15737407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Stern MB; Siderowf A
    Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-motor features of Parkinson's disease: depression and dementia.
    Reichmann H; Schneider C; Löhle M
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S87-92. PubMed ID: 20083017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A2A receptors and Parkinson's disease.
    Morelli M; Carta AR; Jenner P
    Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-motor dysfunction in Parkinson's disease.
    Ziemssen T; Reichmann H
    Parkinsonism Relat Disord; 2007 Aug; 13(6):323-32. PubMed ID: 17349813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norepinephrine: The redheaded stepchild of Parkinson's disease.
    Rommelfanger KS; Weinshenker D
    Biochem Pharmacol; 2007 Jul; 74(2):177-90. PubMed ID: 17416354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
    Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
    Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory dysfunction as a diagnostic marker for Parkinson's disease.
    Haehner A; Hummel T; Reichmann H
    Expert Rev Neurother; 2009 Dec; 9(12):1773-9. PubMed ID: 19951136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A; Pontis S; Borsini F; Morelli M
    Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
    Ross GW; Petrovitch H
    Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.